Pfizer tests new drug cocktail for Hard-to-Treat myeloma

NCT ID NCT05090566

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested elranatamab, a bispecific antibody that helps the immune system attack cancer cells, in combination with other drugs for people with multiple myeloma that had stopped responding to at least three prior treatments. The trial aimed to find the safest dose and see if the combinations could shrink tumors. However, the study was terminated early after enrolling 46 participants, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elranatamab (a bispecific antibody) combined with either nirogacestat or lenalidomide plus dexamethasone
What this could lead to: If successful, this could point toward a new combination treatment for multiple myeloma that has stopped responding to standard therapies.
What could go wrong: The trial was terminated early with only 46 participants, so results are limited. It is still early-stage research, and the combinations may not prove safe or effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, T2N 5G2, Canada
Banner Gateway Medical Center

Gilbert, Arizona, 85234, United States
Banner Gateway Medical Pavilion

Gilbert, Arizona, 85234, United States
Banner Health d.b.a. Banner MD Anderson Cancer Center

Phoenix, Arizona, 85012, United States
Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Beverly Hills Cancer Center

Beverly Hills, California, 90211, United States
Cedars Sinai Medical Center

Los Angeles, California, 90048, United States
Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD

Los Angeles, California, 90048, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)

Los Angeles, California, 90048, United States
Cedars-Sinai Tarzana

Tarzana, California, 91356, United States
Clinical Research Advisors

Encino, California, 91316, United States
Clinical Research Advisors

Los Angeles, California, 90020, United States
Clinical Research Advisors

Los Angeles, California, 90048, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

Coral Gables, Florida, 33146, United States
Sylvester Comprehensive Cancer Center- Deerfield Beach

Deerfield Beach, Florida, 33442, United States
The Johns Hopkins University School of Medicine

Baltimore, Maryland, 21205, United States
The Ottawa Hospital - General Campus

Ottawa, Ontario, K1H 8L6, Canada
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)

Baltimore, Maryland, 21231, United States
UHealth Tower

Miami, Florida, 33136, United States
University of Miami

Coral Gables, Florida, 33146, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.